Mission Statement, Vision, & Core Values (2026) of Jiang Zhong Pharmaceutical Co.,Ltd.

Rooted in a pioneering journey that began in 1996, Jiang Zhong Pharmaceutical Co., Ltd. has evolved into a powerhouse of OTC and prescription manufacturing with its cutting-edge Jiangzhong Medicine Valley-equipped with production lines imported from Europe and America-and a product roster that includes household names like Weiwei Xiaoshi Tablets and Chuyuan Amino Acid Oral Solution; the company reported a robust 2.3 billion RMB in revenue for 2022 (a 15% increase year-over-year), employs over 4,000 professionals with a heavy R&D focus, allocates about 230 million RMB (≈10% of revenue) to innovation, targets a 25% emissions reduction by 2025, and as of December 12, 2025, was trading at 24.38 CNY per share-signals of its mission-driven commitment to quality, a vision to be a first-class global healthcare enterprise, and core values centered on innovation, integrity, inclusiveness, and social responsibility

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) - Intro

• Founded: 1996
• Employees: >4,000 (significant R&D headcount)
• Major manufacturing hub: Jiangzhong Medicine Valley with European/American advanced production lines
• Key brands/products: Jiangzhong Weiwei Xiaoshi Tablets, Compound Coral Calcium Tablets, Liang Sang, Chuyuan Amino Acid Oral Solution

• Deliver safe, effective, and affordable healthcare products across China and select international markets.
• Leverage advanced manufacturing and robust quality systems to ensure product integrity and regulatory compliance.
• Prioritize patient-centered innovation, bridging traditional OTC strengths with modern pharmaceutical R&D.

• Become a leading, trusted Chinese pharmaceutical enterprise recognized for accessible consumer health solutions and competitive prescription medicines.
• Expand product reach domestically and regionally while evolving Jiangzhong Medicine Valley into a center of manufacturing and innovation excellence.
• Drive sustainable growth through quality, diversification, and digital-enabled supply-chain resilience.

• Quality First - uncompromising manufacturing and testing standards across all production lines.
• Patient Focus - product development and commercialization guided by patient needs and safety.
• Innovation - continuous R&D investment to renew product portfolio and formulation technologies.
• Integrity & Compliance - adherence to regulatory requirements and ethical conduct in operations and marketing.
• People & Collaboration - talent development, cross-functional teamwork, and partnerships with academic and industrial peers.

• Manufacturing: Jiangzhong Medicine Valley employs advanced EU/US-imported lines to support scale-up and quality consistency across OTC and prescription SKUs.
• Revenue drivers: 2022 revenue of 2.3 billion RMB (15% YoY growth) attributed to increased production capacity and improved supply-chain efficiency.
• Market signal: stock price at 24.38 CNY on 12 Dec 2025 (+0.12%), reflecting steady investor confidence in corporate strategy and execution.
• Human capital: >4,000 employees with a sizeable R&D cohort to support formulation improvements, new indications, and regulatory submissions.

• Scale manufacturing while maintaining GMP-level quality - continued investment in Jiangzhong Medicine Valley capacity and automation.
• Accelerate R&D commercialization pathways - converting pipeline assets into OTC and prescription revenue streams.
• Strengthen supply-chain resilience - diversify sourcing and digitalize logistics to protect margins and availability.
• Enhance brand equity for flagship SKUs to capture market share in OTC categories and expand presence in hospital procurement for prescription drugs.

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) Overview

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) is committed to research, development, production, and distribution of high-quality pharmaceutical products, with a mission grounded in innovation, integrity, sustainability, and global patient-focused healthcare delivery.

Core elements of the mission include leveraging cutting-edge technology and scientific expertise to deliver safe, effective medications while maintaining ethical manufacturing and environmental responsibility. In 2022 the company allocated roughly 10% of annual revenue to research and development - about 230 million RMB - underscoring its innovation focus. Jiang Zhong has set operational sustainability targets including a goal to reduce emissions by 25% by 2025 and pursues strategic partnerships with healthcare institutions and global pharmaceutical firms to broaden access to quality care.

• Mission emphasis: innovation, integrity, patient safety, and global healthcare access.
• R&D commitment: ~230 million RMB in 2022 (≈10% of revenue).
• Sustainability target: 25% emissions reduction by 2025.
• Strategic focus: partnerships with hospitals, research institutes, and multinational pharma companies.

Strategic pillars and operational priorities that flow from the mission:

• Accelerate pipeline development through sustained R&D investment and adoption of advanced technologies.
• Strengthen quality assurance and regulatory compliance across manufacturing and distribution networks.
• Expand international collaborations to improve global market access and knowledge sharing.
• Implement measurable sustainability initiatives across facilities to meet the 2025 emissions target.

For more investor-focused context and stakeholder information, see: Exploring Jiang Zhong Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) - Mission Statement

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) positions its mission around delivering safe, effective and accessible healthcare solutions while driving sustainable growth and industry innovation. The company emphasizes research-driven product development, expanded market access, and social responsibility as pillars of long-term value creation for patients, partners and shareholders.

• Advance pharmaceutical science through focused R&D investments and strategic collaborations.
• Deliver high-quality medicines and healthcare services to domestic and international markets.
• Create shareholder value via disciplined growth, operational excellence and portfolio optimization.
• Uphold ethical manufacturing, regulatory compliance and patient safety as top priorities.
• Contribute to public health and community welfare through targeted programs and responsible corporate citizenship.

Vision Statement

• Becoming a first-class enterprise in the global pharmaceutical and healthcare markets.
• Setting benchmarks in technological advancement, product diversity, and business models.
• Building strong market competitiveness, industry leadership, and social influence.
• Continuously leading industrial upgrades and promoting social progress through innovation.
• Providing high-quality products and services aligned with evolving global healthcare needs.
• Expanding global presence and influence across therapeutic areas and markets.

Core Strategic Priorities (Operationalising the Vision)

• R&D excellence: focus on small molecules, traditional Chinese medicine modernization and formulation upgrades.
• Market expansion: strengthen pipeline commercialization and international registration efforts.
• Manufacturing & quality: upgrade GMP facilities and digitalize production for scalability.
• Partnerships & M&A: selective alliances to acquire technologies, indications and distribution channels.
• Sustainability & ESG: environmental management, workplace safety and community health programs.

Key Company Metrics and Financial Snapshot

How Vision, Mission and Core Values Translate to Measurable Actions

• Allocate ~6-8% of annual revenue to R&D to drive new formulations and registration filings.
• Pursue 3-5 overseas registrations or partnerships per year to increase international sales penetration.
• Target gross margin improvement through manufacturing optimization and product mix upgrade.
• Implement ESG metrics across operations - emissions reduction, waste treatment and employee safety KPIs.
• Maintain compliance and quality metrics: zero critical GMP findings, continuous batch-release stability >99%.

For investor-focused context and stakeholder engagement details, see: Exploring Jiang Zhong Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) Vision Statement

• Innovate continuously to advance pharmaceutical science and expand therapeutic options for patients.
• Maintain industry-leading quality and compliance across manufacturing, supply chain, and clinical development.
• Foster an inclusive, execution-oriented culture that accelerates product commercialization and market responsiveness.
• Create long-term value for shareholders while fulfilling social responsibility to improve public health.

• Innovation - Prioritizing research, development, and technological adoption to drive new therapies and improve existing products.
• Quality - Upholding strict quality control and regulatory compliance across facilities and product lines.
• Inclusiveness - Building diverse teams and partnering across academia, industry, and communities.
• Excellence - Pursuing operational excellence in manufacturing, clinical trials, and commercialization.
• Execution & Sharing - Translating strategy into measurable outcomes and sharing knowledge internally to scale best practices.
• Integrity - Ensuring transparency, ethical behavior, and trustworthy stakeholder relationships.
• Spirit of Struggle - Encouraging resilience, persistence, and accountability in the face of market and scientific challenges.
• Openness & Learning - Embracing change, continuous education, and evidence-based improvements.
• Social Responsibility - Committing resources and capabilities to public health, access to medicines, and community wellbeing.

• R&D Intensification - Allocate sustained funding to pipeline diversification and biologics/specialty therapies.
• Quality & Compliance - Invest in GMP upgrades, digital quality management, and international certifications.
• Market Expansion - Grow presence in domestic retail, hospital tender channels, and selected export markets.
• Talent & Culture - Strengthen execution culture through training, meritocratic incentives, and collaborative platforms.
• ESG & Social Impact - Integrate environmental, social, and governance targets into corporate strategy and reporting.

• Innovation KPI - Number of active R&D projects, IND/NDA filings per year, and patents granted.
• Quality KPI - Batch release success rate, audit pass rate, and recall frequency.
• Inclusiveness KPI - Diversity metrics, employee retention, and internal mobility rates.
• Execution KPI - Time-to-market for new products, commercial launch success rates, and tender win rates.
• Social Responsibility KPI - Donations/CSR spending, patient access programs, and community health initiatives.

• Integrity is embedded through board oversight, compliance functions, and transparent financial reporting.
• Risk management processes align safety, regulatory, and market risk with strategic decision-making.
• Stakeholder engagement channels include investor relations, healthcare partnerships, and public health collaborations.

• Targeted R&D alliances with academic centers to accelerate specialty drug candidates.
• Quality modernization projects to meet international GMP standards and enable exports.
• Employee development programs to cultivate a culture of execution, shared learning, and innovation.
• Community health campaigns and patient-support programs to enhance medicine access and disease awareness.